We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)
Read MoreHide Full Article
Enanta Pharmaceuticals, Inc. (ENTA - Free Report) is a research and development-focused biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ENTA’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Enanta Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for ENTA
In the past 30 days, two estimates have gone higher for Enanta Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from $1.05 a share 30 days ago, to $1.94 today, a move of 84.8%.
Current Year Estimates for ENTA
Meanwhile, Enanta Pharmaceuticals’ current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 2 cents per share 30 days ago to 97 cents per share today, a significant increase.
The stock has also started to move higher lately, adding 8.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
Image: Bigstock
Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)
Enanta Pharmaceuticals, Inc. (ENTA - Free Report) is a research and development-focused biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ENTA’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Enanta Pharmaceuticals could be a solid choice for investors.
Current Quarter Estimates for ENTA
In the past 30 days, two estimates have gone higher for Enanta Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from $1.05 a share 30 days ago, to $1.94 today, a move of 84.8%.
Current Year Estimates for ENTA
Meanwhile, Enanta Pharmaceuticals’ current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 2 cents per share 30 days ago to 97 cents per share today, a significant increase.
Enanta Pharmaceuticals, Inc. Price and Consensus
Enanta Pharmaceuticals, Inc. Price and Consensus | Enanta Pharmaceuticals, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 8.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
4 Surprising Tech Stocks to Keep an Eye on
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.
See Stocks Now>>